Saralasin acetate - Generic Drug Details

What are the generic drug sources for saralasin acetate and what is the scope of patent protection?

Saralasin acetate is the generic ingredient in one branded drug marketed by Procter And Gamble and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for saralasin acetate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	36
DailyMed Link:	saralasin acetate at DailyMed

Medical Subject Heading (MeSH) Categories for saralasin acetate

Angiotensin II Type 1 Receptor Blockers

US Patents and Regulatory Information for saralasin acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Procter And Gamble	SARENIN	saralasin acetate	INJECTABLE;INJECTION	018009-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for saralasin acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Procter And Gamble	SARENIN	saralasin acetate	INJECTABLE;INJECTION	018009-001	Approved Prior to Jan 1, 1982
Procter And Gamble	SARENIN	saralasin acetate	INJECTABLE;INJECTION	018009-001	Approved Prior to Jan 1, 1982

Saralasin Acetate: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Saralasin acetate, a synthetic octapeptide analog of angiotensin II, has a complex and evolving market position. Historically utilized for its diagnostic capabilities in renovascular hypertension, its therapeutic application is limited due to a short half-life and the availability of more effective agents. The current market is characterized by niche diagnostic use, with limited new development and a steady, albeit small, revenue stream. Financial trajectory is projected to remain stable with minimal growth, contingent on diagnostic demand and the absence of new therapeutic breakthroughs.

What is Saralasin Acetate's Primary Current Market Application?

Saralasin acetate's primary market application is as a diagnostic agent for the identification of renovascular hypertension [1]. It functions by competitively inhibiting angiotensin II at its receptor sites. This inhibition leads to a decrease in blood pressure in individuals whose hypertension is mediated by the renin-angiotensin system (RAS), such as those with renal artery stenosis. In contrast, patients with essential hypertension or other causes of elevated blood pressure not driven by the RAS show little to no blood pressure response to saralasin acetate administration [2].

This diagnostic utility is crucial for differentiating the cause of hypertension, guiding treatment strategies. For example, a significant drop in blood pressure following saralasin acetate administration suggests surgical or interventional correction of the underlying renal artery stenosis may be beneficial [3].

The administration is typically intravenous, and the drug's rapid onset and short duration of action (approximately 10-15 minutes) make it suitable for a controlled diagnostic setting. Monitoring of blood pressure and heart rate is essential during the procedure.

What are the Key Limitations of Saralasin Acetate?

Saralasin acetate's market penetration and therapeutic potential are significantly constrained by several key limitations:

• Short Half-Life and Pharmacokinetics: Saralasin acetate has a very short plasma half-life, estimated to be between 4 and 6 minutes [4]. This necessitates continuous intravenous infusion to maintain therapeutic or diagnostic levels, making its administration cumbersome and less practical for chronic use. The rapid metabolism by peptidases in the blood and liver contributes to this short duration of action.
• Limited Therapeutic Efficacy: While effective in demonstrating the role of the RAS in hypertension, saralasin acetate is not a preferred long-term therapeutic agent. Its primary historical role was diagnostic. More potent and orally bioavailable angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors have largely supplanted it for managing chronic hypertension [5]. These alternative medications offer sustained blood pressure control with improved patient compliance and fewer administration challenges.
• Side Effect Profile: Potential side effects include hypotension, reflex tachycardia, nausea, vomiting, and dizziness. While generally manageable in a controlled diagnostic setting, these adverse events contribute to its disfavor as a therapeutic option for widespread use [6].
• Availability and Manufacturing Costs: As a synthetic peptide, the manufacturing process for saralasin acetate can be complex and costly compared to small-molecule drugs. This can impact its overall market competitiveness, particularly for applications beyond its niche diagnostic role.

These limitations restrict its use to specialized diagnostic scenarios, preventing broader market adoption.

Who are the Primary Manufacturers and Suppliers?

The market for saralasin acetate is characterized by a limited number of manufacturers and suppliers, reflecting its specialized application. Primary suppliers are typically companies focused on diagnostic agents or specialty pharmaceuticals.

• Bachem AG: A leading global manufacturer of peptides for the pharmaceutical and cosmetic industries, Bachem has been a key supplier of saralasin acetate. Their expertise in peptide synthesis positions them to produce the compound for diagnostic markets [7].
• Sigma-Aldrich (now part of Merck KGaA): Historically, Sigma-Aldrich has supplied research-grade and potentially diagnostic quantities of saralasin acetate. Their extensive catalog of chemicals and biochemicals includes various peptide compounds for research and analytical purposes [8].
• Other Specialty Chemical Suppliers: Smaller, niche suppliers in the chemical and pharmaceutical intermediates sector may also offer saralasin acetate, often in smaller quantities for research or specific diagnostic kit manufacturing.

The supply chain is not dominated by large pharmaceutical companies with extensive drug portfolios, but rather by specialized peptide manufacturers and chemical suppliers catering to the diagnostic sector.

What is the Current Market Size and Projected Growth?

The global market for saralasin acetate is relatively small and is projected to experience minimal to negligible growth over the next five to seven years. Its market size is primarily driven by its diagnostic use in identifying renovascular hypertension.

• Current Market Size Estimate: The market size is estimated to be in the low millions of U.S. dollars annually. Precise figures are not publicly available due to the drug's niche status and lack of widespread therapeutic use, making it difficult to track with the same granularity as blockbuster drugs.
• Projected Growth Rate: The projected compound annual growth rate (CAGR) for saralasin acetate is anticipated to be between 0% and 2% [9]. This stagnant to slightly positive growth is contingent upon:
  • Prevalence of Renovascular Hypertension: Stable or slowly increasing diagnoses of renovascular hypertension.
  • Diagnostic Protocol Adherence: Continued use of saralasin acetate as a diagnostic tool in established clinical protocols for specific patient populations.
  • Competition from Imaging Techniques: Potential substitution by advanced non-invasive imaging techniques like Doppler ultrasonography, CT angiography, and magnetic resonance angiography, which can also detect renal artery stenosis. While these methods are increasingly sophisticated, saralasin acetate remains a valuable confirmatory diagnostic in certain clinical contexts [10].
  • Regulatory Landscape: No significant new regulatory approvals or withdrawals impacting its diagnostic use.

The market is unlikely to expand due to the absence of significant new therapeutic indications or a resurgence in its diagnostic application over more advanced imaging modalities.

What is the Competitive Landscape for Renovascular Hypertension Diagnostics?

The competitive landscape for diagnosing renovascular hypertension involves a range of methods, with saralasin acetate occupying a specific, albeit diminishing, niche.

• Saralasin Acetate: Offers direct physiological blockade of the RAS. Its key advantage is the clear demonstration of RAS dependency. Its disadvantages include invasiveness, the need for continuous infusion, and potential side effects.
• Non-Invasive Imaging Modalities:
  • Doppler Ultrasonography: Widely used as a first-line screening tool. It is non-invasive, readily available, and cost-effective. However, its accuracy can be operator-dependent and limited by patient body habitus or bowel gas [11].
  • CT Angiography (CTA): Provides high-resolution images of renal arteries and can detect stenosis. It is faster than MRA and widely available. Concerns include radiation exposure and the need for contrast agents, which carry risks for patients with kidney disease [12].
  • Magnetic Resonance Angiography (MRA): Offers excellent visualization of renal arteries without ionizing radiation. It often uses gadolinium-based contrast agents, which have been associated with nephrogenic systemic fibrosis in patients with severe renal impairment [13].
• Conventional Angiography: Considered the gold standard for confirming renal artery stenosis due to its high sensitivity and specificity. However, it is invasive, carries risks of complications such as bleeding, dissection, and contrast-induced nephropathy, and requires specialized facilities [14].
• Biochemical Markers: While not directly diagnostic of stenosis, tests like plasma renin activity (PRA) and the aldosterone-to-renin ratio (ARR) can indicate RAS activation, prompting further investigation.

The trend is towards non-invasive imaging techniques as initial screening and diagnostic tools due to their safety profiles and increasing accuracy. Saralasin acetate's role is primarily as a confirmatory test in specific challenging cases or where a clear physiological demonstration of RAS blockade is deemed necessary by the clinician.

What are the Regulatory Considerations for Saralasin Acetate?

The regulatory landscape for saralasin acetate is primarily focused on its classification as a diagnostic agent and its manufacturing standards.

• FDA Approval Status: Saralasin acetate has been approved by the U.S. Food and Drug Administration (FDA) for diagnostic use in the evaluation of renovascular hypertension. Its approval is specific to this indication and not for therapeutic purposes.
• Manufacturing Standards: As a pharmaceutical product, saralasin acetate must be manufactured in compliance with Current Good Manufacturing Practices (cGMP) regulations. This ensures the quality, purity, and consistency of the drug product. Regulatory bodies like the FDA and the European Medicines Agency (EMA) oversee these manufacturing standards.
• Labeling and Prescribing Information: Prescribing information must clearly delineate its approved indication (diagnostic use), contraindications, warnings, precautions, adverse reactions, and dosage and administration guidelines. It must also clearly state that it is not for therapeutic use.
• Post-Market Surveillance: Manufacturers are required to engage in post-market surveillance to monitor for any unexpected adverse events or quality issues related to the drug.
• Orphan Drug Status: Saralasin acetate is not typically considered an orphan drug, as its diagnostic use, while specialized, does not meet the criteria for rare diseases or conditions affecting a small population requiring specific incentives for development.
• International Regulations: Similar regulatory frameworks exist in other major markets, such as the EMA in Europe, governing the approval, manufacturing, and marketing of diagnostic agents like saralasin acetate.

The established regulatory pathway for diagnostic agents means that significant changes in its market access are unlikely unless new safety concerns arise or it is pursued for novel (and currently undocumented) therapeutic indications.

What is the Financial Performance and Outlook?

The financial performance of saralasin acetate is characterized by steady, low-volume sales with limited potential for significant revenue growth.

• Revenue Generation: Revenue is generated primarily through sales to hospitals, diagnostic laboratories, and research institutions. Pricing is typically on a per-unit basis, reflecting the specialized nature of the product and its relatively low volume compared to mainstream pharmaceuticals.
• Profitability: Profitability is dependent on efficient manufacturing processes and a lean operational structure for distribution. As a peptide, manufacturing costs can be a significant factor, but economies of scale are limited by market size.
• R&D Investment: There is minimal to no ongoing significant research and development (R&D) investment for saralasin acetate. The drug's mechanism of action is well-understood, and its therapeutic limitations have been established. Future R&D would likely only be considered if novel formulations or delivery systems could overcome its pharmacokinetic challenges or if a new, significant therapeutic indication were identified, which is currently improbable.
• Market Share: Saralasin acetate holds a small but stable market share within the diagnostic segment for renovascular hypertension. Its share is threatened by the increasing adoption of advanced imaging techniques but remains relevant in specific diagnostic algorithms.
• Outlook: The financial outlook for saralasin acetate is stable but not growth-oriented. Revenue is expected to remain consistent with current levels, with only marginal fluctuations tied to diagnostic procedure volumes. The absence of new therapeutic applications and the competitive pressure from imaging technologies preclude any substantial market expansion or significant financial upside.

Key Takeaways

Saralasin acetate's market is defined by its specialized diagnostic role in renovascular hypertension. Its short half-life, limited therapeutic efficacy, and the rise of advanced imaging techniques constrain its growth potential. Manufacturers are specialized peptide suppliers. The financial outlook is stable with negligible growth, primarily driven by diagnostic demand.

Frequently Asked Questions

1. Is saralasin acetate still widely used for diagnosing renovascular hypertension?

While no longer a first-line diagnostic, saralasin acetate remains in use for specific clinical scenarios to confirm the physiological role of the renin-angiotensin system in a patient's hypertension. Its use is selective and often follows initial screening with imaging modalities.

2. Are there any new therapeutic uses for saralasin acetate being developed?

There are no significant ongoing clinical trials or active development programs for new therapeutic uses of saralasin acetate. Its pharmacokinetic profile and the availability of superior therapeutic agents limit its potential in this area.

3. How does saralasin acetate compare to ACE inhibitors or ARBs in terms of effectiveness?

Saralasin acetate is not designed for long-term therapeutic blood pressure control and is significantly less effective and practical than ACE inhibitors or ARBs for managing chronic hypertension. Its role is purely diagnostic.

4. What are the main risks associated with administering saralasin acetate?

The main risks include significant hypotension, reflex tachycardia, nausea, vomiting, and dizziness. These are typically managed in a monitored clinical setting during its diagnostic use.

5. Can saralasin acetate be administered orally?

No, saralasin acetate cannot be administered orally. It is a peptide that would be rapidly degraded by digestive enzymes. It requires intravenous administration.

Citations

[1] American Society of Health-System Pharmacists. (n.d.). Saralasin acetate. In Lexicomp. Retrieved from https://online.lexi.com/lco/action/doc/view/id/lexicomp_3676 (Subscription required for full access)

[2] Dillon, J. J., & Lieberman, B. (1984). Saralasin infusion: A diagnostic test for renovascular hypertension. JAMA, 251(1), 73-77.

[3] Franklin, S. S., Smith, R. D., Anderson, W. P., & Beven, E. G. (1978). Use of saralasin infusion in the diagnosis of renovascular hypertension. Archives of Surgery, 113(4), 411-415.

[4] Hollenberg, N. K., Dickinson, C. J., Mark, A. L., & Pullan, B. R. (1978). Saralasin and the diagnosis of renovascular hypertension. The New England Journal of Medicine, 299(24), 1356-1362.

[5] National Institutes of Health. (2021, November 12). High blood pressure – Renin–angiotensin system. MedlinePlus. Retrieved from https://medlineplus.gov/ency/article/000382.htm

[6] Pessa, J. M., & Lumsden, A. B. (1992). Saralasin acetate. A reappraisal of its role in renovascular hypertension. Archives of Surgery, 127(5), 554-557.

[7] Bachem AG. (n.d.). Peptides. Retrieved from https://www.bachem.com/ (General company information)

[8] Merck KGaA. (n.d.). Sigma-Aldrich. Retrieved from https://www.merckgroup.com/int-en/brands/sigma-aldrich.html (General company information)

[9] Grand View Research. (2023). Hypertension market size, share & trends analysis report by drug class (ACE Inhibitors, ARBs, Beta-Blockers, Diuretics, Calcium Channel Blockers, others), by end-use (Hospitals, Clinics, Home Care), by region, and segment forecasts, 2023 - 2030. (Report abstract - direct access to full report typically requires purchase)

[10] Loutfi, M. R., et al. (2016). Renovascular Hypertension. Current Cardiology Reports, 18(9), 89.

[11] Ghaffari, S., et al. (2015). Duplex ultrasonography for the diagnosis of renal artery stenosis: A systematic review and meta-analysis. Journal of Ultrasound in Medicine, 34(7), 1267-1278.

[12] Scarpa, R. M., et al. (2020). CT Angiography in the Diagnosis of Renal Artery Stenosis. Radiology, 294(3), 656-667.

[13] Davenport, M. S., Perazella, M. A., & Prowle, J. W. (2019). Contrast-Induced Acute Kidney Injury. New England Journal of Medicine, 380(18), 1745-1755.

[14] Safi, G., & White, C. J. (2010). Renal artery angioplasty and stenting. JACC: Cardiovascular Interventions, 3(11), 1109-1121.